• Home
  • » 
  • Reports
  • » 
  • Genotoxicity Testing and Mutagenicity Te...

Genotoxicity Testing Market

Genotoxicity Testing and Mutagenicity Testing Services Market: Distribution by Type of Assay, Assay / Test Offered, End User Industry and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

  • Lowest Price Guaranteed From USD 4,799

  • Published
    February 2023

  • Slides
    174

  • View Count
    8624

  • Buy Now

Example Insights

The image provides context of genotoxicity testing services market. Genotoxicity and mutagenicity testing techniques have the potential to transform the overall safety assessment process of compounds, by overcoming several challenges currently faced by healthcare sector as well as end-users This image provides list of genotoxicity / mutagenicity testing service providers.Presently, over 80 industry and non-industry players are providing genotoxicity and mutagenicity testing services across the globe; majority of these firms are based in Asia-Pacific The infographic looks at the genotoxicity / mutagenicity testing service providers clandscape. Leveraging their expertise, over 70% players use in vitro and in vivo assays to provide genotoxicity / mutagenicity testing services to a range of end users, primarily those engaged in the healthcare sector
The image looks at the competitive landscape across various genotoxicity / mutagenicity testing service providers. In pursuit of building a competitive edge, service providers in this domain are steadily expanding their capabilities in order to cater to the customized requests of their clients This infographic looks at the various partnership deals inked by stakeholders in genotoxicity / mutagenicity testing domain. The growing interest in this field is also evident from the rise in partnership activity; specifically, a large share of deals were acquisitions, highlighting the significant consolidation efforts currently ongoing in this market This image looks at the benchmarking of various publications released related to genotoxicity / mutagenicity testing domain. More than 360 studies related to genotoxicity and mutagenicity have been published since 2018, indicating the growing interest of stakeholders in this domain
This image looks at the details of grants related to genotoxicity / mutagenicity testing domain. Several government organizations have also extended considerable financial support to aid the ongoing research efforts focused on genotoxicity / mutagenicity testing This image looks at the details of patents related to genotoxicity / mutagenicity testing domain. Close to 450 patents related to genotoxicity and mutagenicity have been filed / granted to various industry and non-industry players The image provides segmentaion of genotoxicity / mutagenicity testing services market. The genotoxicity / mutagenicity testing services market is anticipated to grow at a healthy pace in the coming decade; the opportunity is likely to be well distributed across different assays, end users and key regions

Report Description

Mutagenicity Testing And Genotoxicity Testing Market Overview 

Mutagenicity testing and genotoxicity testing market is estimated to be $1.01 billion in 2023 and is anticipated to grow at a CAGR of 7% during the forecast period 2023-2035. Genotoxicity refers to the property of hazardous (physical, chemical and biological) agents to cause damage to genetic information present within a cell. It is worth mentioning that this damage can lead to formation of mutations, activation of mistimed event and direct DNA damage. Further, researchers have been able to link the mutations caused by genetic toxicology to various disease indications, including several oncological and genetic disorders. In addition, it is believed that the changes introduced in the genetic material can be passed down to future cell generations. Similarly, mutagenicity refers to the introduction of transmissible changes to the amount and structure of genetic material of organisms, leading to irreversible changes, known as mutations. Therefore, it is crucial to conduct the mutagenicity testing and genotoxicity testing for the safety assessment of products, with the objective of preventing hazardous chemicals from negatively impacting the human health. In addition, mutagenicity and genotoxicity assays conducted during an early stage of product scale-up, can notify process engineers to consider process modifications in order to prevent the synthesis of an intermediate with significant potential for causing genetic damage. At present, genotoxicity assays are frequently employed across several industries, such as healthcare, chemical, cosmetic, food and agriculture, in order to determine whether a particular compound induces damage. However, since there is no particular test available for identifying all relevant genotoxic endpoints, a series of in vivo and in vitro genotoxicity testing techniques are employed to assess the safety of healthcare compounds. Short-term tests (STTs) are often used as the first step in genotoxicity testing. These tests are relatively inexpensive and quick to perform, and they can be used to screen a large number of substances. Some common STTs include the Ames assay (performed in different strains of Salmonella typhimurium and in Escherichia coli) and the micronucleus assay. These genotoxicity assays usually assess the safety of environmental chemicals and consumer products, as well as investigate the mode of action of suspected carcinogens. Additionally, with the rapid development of next-generation sequencing technology, several new methods for genotoxicity testing have been introduced that can enable players to directly analyze the genetic materials. However, owing to the lack of required chemistry capabilities and limited in-house expertise, the stakeholders have started relying on testing service providers for assessing the safety of their compounds. The service providers offer a range of customized genotoxicity testing services for the toxicity evaluation for drug as well as medical device development as recommended by regulatory agencies in most countries. Overall, the growing demand for testing of healthcare products and the stringent safety requirements established by several regulatory bodies across the globe for the mutagenicity testing and genotoxicity testing of human-use substances, has created lucrative opportunities for genotoxicity testing / mutagenicity testing service providers. 

Key Market Insights

The Mutagenicity Testing and Genotoxicity Testing Market by Type of Assay (In vivo, In vitro and Non-GLP / Screening), Assay / Test Offered (Comet Assay, Micronucleus Assay, Chromosomal Aberration Test, Genetic Mutation Test and Others), End User Industry (Chemical Industry, Healthcare Industry, Agriculture Industry, Cosmetic Industry and Other Industries) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035 market report features an extensive study of the current market landscape, market size and future opportunities for the companies offering genotoxicity testing services and / or mutagenicity testing services, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the industry. Key takeaways of the mutagenicity testing and genotoxicity testing market are briefly discussed below.

Genotoxicity Testing and Mutagenicity Testing to Ensure Safety and Regulatory Compliance during Drug Development

Mutagenicity and genotoxicity assays are considered to be crucial in ensuring the safety of substances intended for human consumption. Specifically in the case of pharmaceuticals, potential sources of endotoxins include water, packaging components, equipment, and chemical / raw materials used during the development and manufacturing of a drug product. As a result, genetic toxicology testing is a necessary regulatory requirement for approving new drugs. In fact, mutagenicity testing and genotoxicity testing have been integrated into early-stage drug discovery, allowing the identification of compounds with genotoxic liabilities prior to further drug development. This helps avoid costly setbacks and delays in project timelines.

Types of Genotoxicity Testing and Mutagenicity Testing Services

In order to test mutagenicity and carcinogenicity properties, several standard assays are currently in use. These tests can broadly be divided into two main categories, namely in vitro assays and in vivo assays. In vitro assays are conducted using cells and microorganisms, and they are relatively quick to perform. Some common in vitro genotoxic assays include the Ames assay, micronucleus assay, chromosomal aberration assay, genetic mutation assay, and the comet assay. After the in vitro study, if there is any positive response, a follow-up in vivo study of the same endpoint is usually recommended. In vivo assays are conducted in live animals such as mice or rats, and they are more expensive and time-consuming than in vitro assays. However, these genotoxic assays provide more information about the mechanism of action of test compounds. In addition to the standard genotoxicity assays, there are a number of advanced assays, such as ToxTracker® assay, 3D cell culture assay and high-throughput screening assay that are being developed to improve understanding of the mechanisms of genotoxicity and mutagenicity.

Need for Outsourcing Mutagenicity Testing / Genotoxicity Testing to Contract Service Providers

A number of companies currently lack the expertise to conduct the biological study of a compound due to limited in-house capabilities and inadequate availability of resources. These limitations have encouraged several organizations to outsource the genotoxicity testing / mutagenicity testing, in order to leverage the relevant experience and expertise of contract service providers. Businesses can capitalize on the experience and advanced technologies offered by the contract service providers, thereby streamlining the testing process and expediating the time-to-market products. Further, outsourcing mutagenicity testing and genotoxicity testing optimizes in-house resource allocation, allowing stakeholders to focus on core research and development efforts.

Service Providers Landscape: Players Offering Genotoxicity Testing and Mutagenicity Testing Service

At present, more than 80 industry and non-industry players offer a variety of assays, such as Ames assay, micronucleus assay, chromosomal aberration test, genetic mutation assay and comet assay, which can be used to evaluate the genetic toxicity of a substance. These services are offered across more than 115 facilities across the world. It is worth highlighting that Asia-Pacific is the current hub for providing genotoxicity testing and mutagenicity testing services, featuring the presence of nearly 40% of the total service facilities.

Grants Analysis: More than 280 Grants Awarded to Various Organizations Focused on Mutagenicity Testing / Genotoxicity Testing, since 2018

Over the past few years, various non-profit organizations have extended financial support to aid research related to genotoxicity and mutagenicity. Interestingly, the majority of the grants offered in this market segment are administered by National Institute of Environmental Health Sciences (NIEHS) and National Institute of Allergy and Infectious Diseases (NIAID). Over 90% of the grants have been awarded for a time period of less than 5 years for projects in this sector. 

Publications Analysis: The Growing Scientific Literature Indicates the Active R&D Efforts by Stakeholders for Mutagenicity / Genotoxicity Testing 

Over 360 articles focused on genotoxicity / mutagenicity testing have been published in high-impact journals, since 2018. It is worth noting that, a considerably high share of these publications are research articles focused on evaluating the use of genetic toxicity testing in different types of compounds. Further, MDPI emerged as the most popular publisher with more than 80 publications focused on in vitro and in vivo genetic toxicology assessment

Key Industries Catered by Mutagenicity / Genotoxicity Testing Service Providers

Genotoxicity / mutagenicity testing is employed across various industries, such as healthcare industry (pharmaceutical / biotechnology), chemical industry, cosmetic industry, agriculture industry and food industry.

Key Drivers of Mutagenicity and Genotoxicity Testing Market Growth: Stringent Regulatory Mandates, Consumer Heath Concerns and Advancements in Genetic Toxicology Testing Technology

The genotoxicity testing and mutagenicity testing market is growing rapidly in response to the increasing demand for safe and effective healthcare products and the growing awareness of the public about the risks of genotoxic substances. Further, increased environmental impact of chemicals is driving companies to assess the genotoxic potential of their products in order to protect the ecosystem. Driven by the continuous efforts of industry stakeholders and considerable investments for exploring genetic toxicology, the mutagenicity testing and genotoxicity testing market is anticipated to witness substantial market growth during the forecast period. 
 
Market Analysis: Mutagenicity and Genotoxicity Testing Services Market Size

The mutagenicity and genotoxicity testing services market is estimated to be worth USD 1,011 million in 2023. This value is projected to grow at a CAGR of 7%, during the forecast period 2023-2035. Specifically, in terms of the type of test, the market is anticipated to be driven by in-vitro tests. However, non-GLP / screening is estimated to grow at a significant pace over the coming years. Additionally, it is worth highlighting that the majority of the current market share is captured by companies based in North America.

Leading Mutagenicity Testing and Genotoxicity Testing Service Providers

Examples of the key service providers in this industry (the complete list of companies is available in the full market report) include BioReliance, Charles River Laboratories, Eurofins Scientific, Jai Research Foundation, MB Biosciences, Syngene and Toxys. This market report includes an easily searchable excel database of all the companies providing mutagenicity testing and genotoxicity testing services worldwide.

Recent Developments in Genotoxicity Testing Market

Several recent developments have taken place in the field of genotoxicity testing. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In July 2023, Toxys announced a training workshop for the ToxTracker® genotoxicity assay. The workshop is going to take place in October 2023, at Oegstgeest, The Netherlands. 
  • In April 2023, Nelson Labs received Accreditation Scheme for Conformity Assessment (ASCA) Accreditation from the FDA, adding on to the credibility of the company to offer safe genotoxicity testing assays.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in the mutagenicity testing and genotoxicity testing market, across different segments, as defined in the below table: 

Report Attribute Details

Forecast Period

2023 – 2035
Market Size 2023 $ 1.01 Billion
CAGR 7%

Type of Assay
  • In vivo
  • In vitro
  • Non-GLP / Screening

Assay / Test Offered
  • Comet Assay 
  • Micronucleus Assay 
  • Chromosomal Aberration Test 
  • Genetic Mutation Test and Others

End User Industry
  • Chemical Industry 
  • Healthcare Industry 
  • Agriculture Industry
  • Cosmetic Industry
  • Other Industries

Key Geographical Regions
  • North America 
  • Europe 
  • Asia-Pacific 
  • Latin America 
  • Middle East and North Africa

Key Companies Profiled
  • Aurigene Pharmaceutical Services 
  • Charles River Laboratories 
  • GLR Laboratories 
  • LabCorp 
  • LSIM Safety Institute Sai LifeSciences 
  • Syngene
(Full list of 80+ companies captured available in the report)
Customization Scope

15% Free Customization Option (equivalent to 5 analysts working days)

Excel Data Packs (Complimentary)
  • Market Landscape Analysis 
  • Benchmarking Analysis 
  • Publication Analysis 
  • Academic Grant Analysis 
  • Partnerships and Collaborations Analysis 
  • Patent Analysis 
  • Market Forecast and Opportunity Analysis

The market research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market report includes:

  • An executive summary of the insights captured during our research, offering a high-level view on the current state of the genotoxicity testing and mutagenicity testing services market and its likely evolution in the short to mid and long term.
  • A general overview of genotoxicity and mutagenicity, along with information on its detrimental effects, mechanism and testing techniques employed, key applications, recent developments in the market and future perspectives.
  • A detailed assessment of the overall market landscape of genotoxicity testing and mutagenicity testing service providers, based on several relevant parameters, including year of establishment, company size (in terms of number of employees), location of headquarters, type of organization, location of the facility, type of operation (genotoxicity and mutagenicity), type of offering (service, and reagents and consumables), type of assay(s) (in vitro, in vivo and Non-GLP / Screening), assay(s) / test(s) offered (ames test, micronucleus test, chromosomal aberration test, genetic mutation assay, comet assay and others), end user industry (healthcare industry, chemical  industry, agriculture industry, cosmetic industry, food industry and other industries) and type of testing system(s) (bacteria, animals and novel technology)  
  • An insightful benchmark analysis of various genotoxicity testing and mutagenicity testing service providers segregated into three peer groups, based on location of their headquarters (North America, Europe, and Asia Pacific), highlighting the top companies in this industry, in terms of their respective capabilities.
  • Elaborate profiles of genotoxicity testing and mutagenicity testing service providers. Each profile includes a brief overview of the company, details related to its financial information (if available), testing services portfolio, recent developments and an informed future outlook.
  • An in-depth analysis of various publications related to genotoxicity and mutagenicity, based on several relevant parameters, such as year of publication, type of article, popular publishers (in terms of number of publications), popular journals (in terms of number of number of publications), journal impact factor and popular journals (in terms of journal impact factor). It also includes a publication timeline analysis (by article type and journal impact factor), along with benchmarking of publications to develop more insightful opinions on the recent trends related to research and development in this area.
  • A detailed review of academic grants that have been awarded to various research institutes for projects focused on genotoxicity and mutagenicity, since 2018, based on several parameters, such as year of grant award, amount awarded, funding institute centre, administering institute centre, support period, purpose of grant, activity code, type of recipient organization, location  of recipient organization, study section involved, type of grant application, popular NIH departments (in terms of number of grants), prominent program officers (in terms of number of grants) and popular recipient organizations (in terms of number of grants).
  • A detailed analysis of recent partnerships inked between stakeholders engaged in this industry, since 2018, based on several relevant parameters, such as year of partnership, type of partnership, most active players (in terms of number of partnerships) and regional distribution of partnership activity in genotoxicity testing and mutagenicity testing market.
  • An in-depth analysis of various patents that have been filed / granted related to genotoxicity and mutagenicity, since 2018, taking into consideration parameters, such as type of patent, publication year, geographical region, CPC symbols, leading players (in terms of number of patents filled / granted) and type of applicant, along with a detailed patent benchmarking analysis and an insightful valuation analysis, highlighting the leading patents (in terms of number of citations).

One of the key objectives of the market report was to estimate the current market size, opportunity and the future growth potential of genotoxicity and mutagenicity testing services market in the forecast period. We have provided informed estimates on the likely evolution of the market in the mid-term to long-term for the forecast period, 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of assay (in vivo, in vitro and non-GLP / screening), assay / test offered (comet assay, micronucleus assay, chromosomal aberration test, genetic mutation test and others), end user industry (chemical industry, healthcare industry, agriculture industry, cosmetic industry and other industries) and key geographical regions (North America, Europe, Asia- Pacific, Latin America, and Middle East and North Africa). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is the test for genotoxicity?

Answer: Genotoxicity assays are laboratory tests designed to identify substances that can cause DNA damage or interfere with the cell's genetic material leading to chromosomal aberrations. These assays are essential for evaluating the potential hazards of various chemicals that have the potential to cause cancer, birth defects, or other adverse health effects. The type of genotoxic assays performed vary depending on the substance being tested and the intended use of the test results.

Question 2: What is an example of genotoxicity?

Answer: A genotoxin is a chemical agent capable of causing DNA or chromosomal damage. Thalidomide is a well-known example of a drug that could have been prevented from causing severe birth defects if it had been properly tested for genotoxicity. Thalidomide was a sedative drug that was prescribed to pregnant women in the 1950s to relieve nausea. However, it caused severe fetal abnormalities, including limb defects and the absence of normal openings of the gastrointestinal tract, in thousands of children worldwide. The thalidomide tragedy led to the adoption of more rigorous testing procedures and regulations for the pharmaceutical industry.

Question 3: What is a genotoxicity test for medical devices?

Answer: Genotoxicity testing is crucial for the risk assessment of medical devices. To evaluate the genotoxic risk of medical devices, manufacturing additives as well as the residual components of the devices are evaluated for their potential to damage DNA. This is followed by extractable and leachable (E&L) studies to understand the clinical exposures to the constituent chemicals.

Question 4: What is the importance of mutagenicity testing?

Answer: Mutagenicity testing aids in identification as well as quantification of natural or man-made mutagens from samples. The data gathered from mutagenicity testing is widely accepted as a means of predicting long-term risks associated with cancer in somatic cells or heritable mutations in germ cells.

Question 5: What is an example of mutagenicity?

Answer: Examples of chemical mutagens include alkylating agents and azides, which induce point mutations in the DNA. Biological mutagens often consist of viruses as well as different bacterial strains that can lead to gene mutations. Apart from the aforementioned hazardous agents that cause unintended adverse effects, there are several drugs which present therapeutic mutagenic action. For instance, streptomycin is mutagenic for the tubercle bacillus.

Question 6: What is the anticipated market growth rate of mutagenicity testing and genotoxicity testing market?

Answer: The mutagenicity testing and genotoxicity testing market is expected to grow at a CAGR of 7%, during the forecast period from 2023 to 2035.

Question 7: Which region will lead the mutagenicity testing and genotoxicity testing market?

Answer: North America is anticipated to drive majority of the market revenues, by 2035. In addition, the market in Asia-Pacific is likely to grow at a relatively faster pace, in the long term.

Question 8: Which segment, in terms of type of assay offered, dominates the mutagenicity testing and genotoxicity testing market?

Answer: Currently, in vivo assays dominate the mutagenicity testing and genotoxicity testing market. However, in the foreseen future, in vitro assays are expected to influence the market growth with a higher share in 2035.

Question 9: Which segment, in terms of type of end user, accounts for the largest market share in the mutagenicity testing and genotoxicity testing market?

Answer: Chemical industries are anticipated to capture over 65% of the market share by 2035. In addition, the market for healthcare industries is likely to grow at a relatively faster pace, in the long term.

Question 10: What type of partnership models are most commonly being adopted by stakeholders engaged in mutagenicity testing and genotoxicity testing market?

Answer: Acquisitions emerged as the most popular type of partnership model adopted by companies engaged in offering genotoxicity and mutagenicity testing services. This is followed by platform licensing agreements and service alliances.

Contents

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Detrimental Effects of Genotoxins / Mutagens
3.3. Mechanism of Genotoxicity / Mutagenicity
3.4. Techniques Employed for Genotoxicity Testing / Mutagenicity Testing
3.5. Applications of Genotoxicity / Mutagenicity
3.6. Recent Developments and Future Perspectives

4. MARKET LANDSCAPE
4.1. Genotoxicity Testing / Mutagenicity Testing Service Providers: Overall Market Landscape
4.1.1. Analysis by Type of Operation
4.1.2. Analysis by Type of Offering
4.1.3. Analysis by Regulatory Compliance
4.1.4. Analysis by Type of Assay(s)
4.1.5. Analysis by Assay(s) / Test(s) Offered
4.1.6. Analysis by End User Industry
4.1.7. Analysis by Type of Testing System(s)
4.1.8. Analysis by Custom Testing Services Offered
4.1.9. Analysis by Company Size and Type of Assay
4.1.10. Analysis by Assay / Test Offered and Type of Organization

4.2. Genotoxicity Testing / Mutagenicity Testing: Service Provider Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Organization
4.2.5. Analysis by Location of Facility

5. BENCHMARKING ANALYSIS
5.1. Scope and Methodology
5.2. Assumptions and Key Parameters
5.3. Parameters Scoring
5.4. Benchmarking Analysis: Players based in North America
5.5. Benchmarking Analysis: Players based in Europe
5.6. Benchmarking Analysis: Players based in Asia-Pacific

6. COMPANY PROFILES
6.1. Aurigene Pharmaceutical Services
6.1.1. Company Overview
6.1.2. Service Portfolio
6.1.3. Recent Developments and Future Outlook

6.2. Charles River Laboratories
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Service Portfolio
6.2.4. Recent Developments and Future Outlook

6.3. GLR Laboratories
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Recent Developments and Future Outlook

6.4. LabCorp
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Service Portfolio
6.4.4. Recent Developments and Future Outlook

6.5. LSIM Safety Institute
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Future Outlook

6.6. Sai Life Sciences
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Service Portfolio
6.6.4. Recent Developments and Future Outlook

6.7. Syngene
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Service Portfolio
6.7.4. Recent Developments and Future Outlook

7. PUBLICATION BENCHMARKING ANALYSIS
7.1. Scope and Methodology
7.2. Assumptions and Key Parameters
7.3. Analysis by Year of Publication
7.4. Analysis by Type of Article
7.5. Popular Journals: Analysis by Number of Publications
7.6. Popular Publishers: Analysis by Number of Publications
7.7. Analysis by Journal Impact Factor
7.8. Popular Journals: Analysis by Journal Impact Factor
7.9. Publication Timeline Analysis
7.10. Publication Benchmarking Methodology
7.11. Publication Benchmarking Analysis
7.12. List of Top 10 Publications

8. GRANTS ANALYSIS
8.1. Scope and Methodology
8.2. Assumptions and Key Parameters
8.3. Analysis by Year of Grant Award
8.4. Analysis by Amount Awarded
8.5. Analysis by Funding Institute Center
8.6. Analysis by Administering Institute Center
8.7. Analysis by Support Period
8.8. Popular Recipient Organizations: Analysis by Number of Grants
8.9. Analysis by Type of Recipient Organization
8.10. Analysis by Purpose of Grant
8.11. Analysis by Study Section
8.12. Popular NIH Departments: Analysis by Number of Grants
8.13. Analysis by Administering Institute Center and Support Period
8.14. Analysis by Type of Grant Application
8.15. Analysis by Grant Activity Code
8.16. Prominent Program Officers: Analysis by Number of Grants
8.17. Analysis by Location of Recipient Organization

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Partnership Models
9.2. Assumptions and Key Parameters
9.3. Genotoxicity Testing / Mutagenicity Testing: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partnership and Type of Partner
9.3.5. Analysis by Year of Partnership and Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships

9.3.7. Analysis by Region
9.3.7.1. Intercontinental and Intracontinental Deals

9.3.8. Word Cloud Analysis: Emerging Focus Areas

10. PATENT ANALYSIS
10.1. Scope and Methodology
10.2. Assumptions and Key Parameters
10.3. Genotoxicity Testing and Mutagenicity Testing: List of Patents
10.4. Analysis by Type of Patent
10.5. Analysis by Patent Publication Year
10.6. Analysis by Annual Number of Granted Patents
10.7. Analysis by Geographical Location
10.8. Analysis by Jurisdiction
10.9. Analysis by CPC Symbols
10.10. Analysis by Type of Applicant
10.11. Analysis by Patent Age
10.12. Word Cloud: Emerging Focus Areas
10.13. Leading Industry Players: Analysis by Number of Patents
10.14. Leading Non-Industry Players: Analysis by Number of Patents
10.15. Leading Individual Assignees: Analysis by Number of Patents
10.16. Leading Players: Benchmarking by Patent Characterization (CPC Symbols)

10.17. Patent Valuation: Analysis Methodology and Parameters
10.17.1. Analysis by Relative Patent Valuation

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Forecast Methodology and Key Assumptions
11.2. Global Genotoxicity Testing / Mutagenicity Testing Market, 2023-2035
11.2.1. Genotoxicity Testing / Mutagenicity Testing Market: Analysis by Type of Assay, 2023 and 2035
11.2.1.1. Genotoxicity Testing / Mutagenicity Testing Market for In vivo Assays, 2023-2035
11.2.1.2. Genotoxicity Testing / Mutagenicity Testing Market for In vitro Assays, 2023-2035
11.2.1.3. Genotoxicity Testing / Mutagenicity Testing Market for Non-GLP / Screening Assays, 2023-2035
 
11.2.2. Genotoxicity Testing / Mutagenicity Testing Market: Analysis by Assay / Test Offered, 2023 and 2035
11.2.2.1. Genotoxicity Testing / Mutagenicity Testing Market for Comet Assays, 2023-2035
11.2.2.2. Genotoxicity Testing / Mutagenicity Testing Market for Micronucleus Assays, 2023-2035
11.2.2.3. Genotoxicity Testing / Mutagenicity Testing Market for Chromosomal Aberration Tests, 2023-2035
11.2.2.4. Genotoxicity Testing / Mutagenicity Testing Market for Genetic Mutation Tests, 2023-2035
11.2.2.5. Genotoxicity Testing / Mutagenicity Testing Market for Other Tests, 2023-2035

11.2.3. Genotoxicity Testing / Mutagenicity Testing Market: Analysis by End User Industry, 2023 and 2035
11.2.3.1. Genotoxicity Testing / Mutagenicity Testing Market for Chemical Industry 2023-2035
11.2.3.2. Genotoxicity Testing / Mutagenicity Testing Market for Healthcare Industry, 2023-2035
11.2.3.3. Genotoxicity Testing / Mutagenicity Testing Market for Agriculture Industry, 2023-2035
11.2.3.4. Genotoxicity Testing / Mutagenicity Testing Market for Cosmetic Industry, 2023-2035
11.2.3.5. Genotoxicity Testing / Mutagenicity Testing Market for Other Industries, 2023-2035

11.2.4. Genotoxicity Testing / Mutagenicity Testing Market: Analysis by Geographical Region, 2023 and 2035
11.2.4.1. Genotoxicity Testing / Mutagenicity Testing Market in North America, 2023-2035
11.2.4.2. Genotoxicity Testing / Mutagenicity Testing Market in Europe, 2023-2035
11.2.4.3. Genotoxicity Testing / Mutagenicity Testing Market in Asia-Pacific, 2023-2035
11.2.4.4. Genotoxicity Testing / Mutagenicity Testing Market in Latin America, 2023-2035
11.2.4.5. Genotoxicity Testing / Mutagenicity Testing Market in Middle East and North Africa, 2023-2035

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
 

List Of Figures

Figure 3.1 Detrimental Effects on Potential Targets of Genotoxins / Mutagens
Figure 3.2 Mechanism of Genotoxicity / Mutagenicity
Figure 4.1 Genotoxicity Testing / Mutagenicity Testing: Distribution by Type of Operation
Figure 4.2 Genotoxicity Testing / Mutagenicity Testing: Distribution by Type of Offering
Figure 4.3 Genotoxicity Testing / Mutagenicity Testing: Distribution by Regulatory Compliance
Figure 4.4 Genotoxicity Testing / Mutagenicity Testing: Distribution by Type of Assay(s)
Figure 4.5 Genotoxicity Testing / Mutagenicity Testing: Distribution by Assay(s) / Test(s) Offered
Figure 4.6 Genotoxicity Testing / Mutagenicity Testing: Distribution by End User Industry
Figure 4.7 Genotoxicity Testing / Mutagenicity Testing: Distribution by Type of Testing System(s)
Figure 4.8 Genotoxicity Testing / Mutagenicity Testing: Distribution by Custom Testing Services Offered
Figure 4.9 Genotoxicity Testing / Mutagenicity Testing: Distribution by Company Size and Type of Assay
Figure 4.10 Genotoxicity Testing / Mutagenicity Testing: Distribution by Assay Offered and Type of Organization
Figure 4.11 Genotoxicity Testing / Mutagenicity Testing Service Providers: Distribution by Year of Establishment
Figure 4.12 Genotoxicity Testing / Mutagenicity Testing Service Providers: Distribution by Company Size
Figure 4.13 Genotoxicity Testing / Mutagenicity Testing Service Providers: Distribution by Location of Headquarters
Figure 4.14 Genotoxicity Testing / Mutagenicity Testing Service Providers: Distribution by Type of Organization
Figure 4.15 Genotoxicity Testing / Mutagenicity Testing Service Providers: Distribution by Location of Facility
Figure 5.1 Company Competitiveness: Players based in North America
Figure 5.2 Benchmarking Analysis: Leading Players in North America
Figure 5.3 Company Competitiveness: Players based in Europe
Figure 5.4 Benchmarking Analysis: Leading Players in Europe
Figure 5.5 Company Competitiveness: Players based in Asia-Pacific
Figure 5.6 Benchmarking Analysis: Leading Players in Asia-Pacific
Figure 6.1 Charles River Laboratories: Financial Information
Figure 6.2 LabCorp: Financial Information
Figure 6.3 Sai Life Sciences: Financial Information
Figure 6.4 Syngene: Financial Information
Figure 7.1 Publication Benchmarking: Distribution by Year of Publication
Figure 7.2 Publication Benchmarking: Distribution by Type of Article
Figure 7.3 Popular Journals: Distribution by Number of Publications
Figure 7.4 Popular Publishers: Distribution by Number of Publications
Figure 7.5 Publication Benchmarking: Distribution by Journal Impact Factor
Figure 7.6 Popular Journals: Distribution by Journal Impact Factor
Figure 7.7 Publication Timeline Analysis: Distribution by Article Type
Figure 7.8 Publication Timeline Analysis: Distribution by Journal Impact Factor
Figure 7.9 Publication Benchmarking Analysis
Figure 8.1 Grants Analysis: Distribution by Year of Grant Award
Figure 8.2 Grants Analysis: Distribution by Amount Awarded
Figure 8.3 Grants Analysis: Distribution by Funding Institute Center
Figure 8.4 Grants Analysis: Distribution by Administering Institute Center
Figure 8.5 Grants Analysis: Distribution by Support Period
Figure 8.6 Popular Recipient Organizations: Distribution by Number of Grants
Figure 8.7 Grants Analysis: Distribution by Type of Recipient Organization
Figure 8.8 Grants Analysis: Distribution by Purpose of Grant
Figure 8.9 Grants Analysis: Distribution by Study Section
Figure 8.10 Popular NIH Departments: Distribution by Number of Grants
Figure 8.11 Grants Analysis: Distribution by Administering Institute Center and Support Period
Figure 8.12 Grants Analysis: Distribution by Type of Grant Application
Figure 8.13 Grants Analysis: Distribution by Grant Activity Code
Figure 8.14 Prominent Program Officers: Distribution by Number of Grants
Figure 8.15 Grants Analysis: Distribution by Location of Recipient Organizations
Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 9.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 9.6 Most Active Players: Distribution by Number of Partnerships
Figure 9.7 Partnerships and Collaborations: Distribution by Region
Figure 9.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 9.9 Word Cloud Analysis: Emerging Focus Areas
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Distribution by Patent Publication Year
Figure 10.3 Patent Analysis: Distribution by Annual Number of Granted Patents
Figure 10.4 Patent Analysis: Distribution by Geographical Location
Figure 10.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 10.6 Patent Analysis: Distribution by CPC Symbols
Figure 10.7 Patent Analysis: Distribution by Type of Applicant
Figure 10.8 Patent Analysis: Distribution by Patent Age
Figure 10.9 Word Cloud: Emerging Focus Areas
Figure 10.10 Leading Industry Players: Distribution by Number of Patents
Figure 10.11 Leading Non-Industry Players: Distribution by Number of Patents
Figure 10.12 Leading Individual Assignees: Distribution by Number of Patents
Figure 10.13 Leading Players: Benchmarking by Patent Characterization (CPC Symbols)
Figure 10.14 Patent Valuation: Distribution by Relative Patent Valuation
Figure 11.1 Global Genotoxicity Testing / Mutagenicity Testing Market, 20232-2035 (USD Million)
Figure 11.2 Genotoxicity Testing / Mutagenicity Testing Market, 2023-2035: Distribution by Type of Assay
Figure 11.3 Genotoxicity Testing / Mutagenicity Testing Market for In vivo Assays, 2023-2035 (USD Million)
Figure 11.4 Genotoxicity Testing / Mutagenicity Testing Market for In vitro Assays, 2023-2035 (USD Million)
Figure 11.5 Genotoxicity Testing / Mutagenicity Testing Market for Non-GLP / Screening Assays, 2023-2035 (USD Million)
Figure 11.6 Genotoxicity Testing / Mutagenicity Testing Market, 2023-2035: Distribution by Assay / Test Offered
Figure 11.7 Genotoxicity Testing / Mutagenicity Testing Market for Comet Assays, 2023-2035 (USD Million)
Figure 11.8 Genotoxicity Testing / Mutagenicity Testing Market for Micronucleus Assays, 2023-2035 (USD Million)
Figure 11.9 Genotoxicity Testing / Mutagenicity Testing Market for Chromosomal Aberration Tests, 2023-2035 (USD Million)
Figure 11.10 Genotoxicity Testing / Mutagenicity Testing Market for Genetic Mutation Tests, 2023-2035 (USD Million)
Figure 11.11 Genotoxicity Testing / Mutagenicity Testing Market for Other Tests, 2023-2035 (USD Million)
Figure 11.12 Genotoxicity Testing / Mutagenicity Testing Market, 2023-2035: Distribution by End User Industry
Figure 11.13 Genotoxicity Testing / Mutagenicity Testing Market for Chemical Industry, 2023-2035 (USD Million)
Figure 11.14 Genotoxicity Testing / Mutagenicity Testing Market for Healthcare Industry, 2023-2035 (USD Million)
Figure 11.15 Genotoxicity Testing / Mutagenicity Testing Market for Agriculture Industry, 2023-2035 (USD Million)
Figure 11.16 Genotoxicity Testing / Mutagenicity Testing Market for Cosmetic Industry, 2023-2035 (USD Million)
Figure 11.17 Genotoxicity Testing / Mutagenicity Testing Market for Other Industries, 2023-2035 (USD Million)
Figure 11.18 Genotoxicity Testing / Mutagenicity Testing Market, 2023 and 2035: Distribution by Geographical Region
Figure 11.19 Genotoxicity Testing / Mutagenicity Testing Market in North America, 2023-2035 (USD Million)
Figure 11.20 Genotoxicity Testing / Mutagenicity Testing Market in Europe, 2023-2035 (USD Million)
Figure 11.21 Genotoxicity Testing / Mutagenicity Testing Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 11.22 Genotoxicity Testing / Mutagenicity Testing Market in Latin America, 2023-2035 (USD Million)
Figure 11.23 Genotoxicity Testing / Mutagenicity Testing Market in Middle East and North Africa, 2023-2035 (USD Million) 
 

List Of Tables

Table 3.1 Standard Test for Genotoxicity
Table 4.1 List of Genotoxicity / Mutagenicity Testing Service Providers
Table 6.1 Aurigene Pharmaceutical Services: Service Portfolio
Table 6.2 Aurigene Pharmaceutical Services: Recent Developments and Future Outlook
Table 6.3 Charles River Laboratories: Service Portfolio
Table 6.4 Charles River Laboratories: Recent Developments and Future Outlook
Table 6.5 GLR Laboratories: Service Portfolio
Table 6.6 GLR Laboratories: Recent Developments and Future Outlook
Table 6.7 LabCorp: Service Portfolio
Table 6.8 LabCorp: Recent Developments and Future Outlook
Table 6.9 LSIM Safety Institute: Service Portfolio
Table 6.10 LSIM Safety Institute: Future Outlook
Table 6.11 Sai Life Sciences: Service Portfolio
Table 6.12 Sai Life Sciences: Recent Developments and Future Outlook
Table 6.13 Syngene: Service Portfolio
Table 6.14 Syngene: Recent Developments and Future Outlook
Table 7.1 Genotoxicity / Mutagenicity Testing: List of Publications
Table 7.2 List of Top 10 Publications
Table 8.1 Genotoxicity Testing / Mutagenicity Testing: List of Grants
Table 9.1 Genotoxicity Testing / Mutagenicity Testing Services: List of Partnerships and Collaborations
Table 10.1 Genotoxicity Testing / Mutagenicity Testing: List of Patents
Table 12.1 Genotoxicity Testing / Mutagenicity Testing: Distribution by Type of Operation
Table 12.2 Genotoxicity Testing / Mutagenicity Testing: Distribution by Type of Offering
Table 12.3 Genotoxicity Testing / Mutagenicity Testing: Distribution by Regulatory Compliance
Table 12.4 Genotoxicity Testing / Mutagenicity Testing: Distribution by Type of Assay(s)
Table 12.5 Genotoxicity Testing / Mutagenicity Testing: Distribution by Assay(s) / Test(s) Offered
Table 12.6 Genotoxicity Testing / Mutagenicity Testing: Distribution by End User Industry
Table 12.7 Genotoxicity Testing / Mutagenicity Testing: Distribution by Type of Testing System(s)
Table 12.8 Genotoxicity Testing / Mutagenicity Testing: Distribution by Custom Testing Services Offered
Table 12.9 Genotoxicity Testing / Mutagenicity Testing: Distribution by Company Size and Type of Assay
Table 12.10 Genotoxicity Testing / Mutagenicity Testing: Distribution by Assay / Test Offered and Type of Organization
Table 12.11 Genotoxicity Testing / Mutagenicity Testing Service Providers: Distribution by Year of Establishment
Table 12.12 Genotoxicity Testing / Mutagenicity Testing Service Providers: Distribution by Company Size
Table 12.13 Genotoxicity Testing / Mutagenicity Testing Service Providers: Distribution by Location of Headquarters
Table 12.14 Genotoxicity Testing / Mutagenicity Testing Service Providers: Distribution by Type of Organization
Table 12.15 Genotoxicity Testing / Mutagenicity Testing Service Providers: Distribution by Location of Facility
Table 12.16 Charles River Laboratories: Financial Information
Table 12.17 LabCorp: Financial Information
Table 12.18 Syngene: Financial Information
Table 12.19 Sai Life Sciences: Financial Information
Table 12.20 Publication Benchmarking: Distribution by Year of Publication
Table 12.21 Publication Benchmarking: Distribution by Type of Article
Table 12.22 Popular Journals: Distribution by Number of Publications
Table 12.23 Popular Publishers: Distribution by Number of Publications
Table 12.24 Publication Benchmarking: Distribution by Journal Impact Factor
Table 12.25 Popular Journals: Distribution by Journal Impact Factor
Table 12.26 Grants Analysis: Distribution by Year of Grant Award
Table 12.27 Grants Analysis: Distribution by Amount Awarded
Table 12.28 Grants Analysis: Distribution by Funding Institute Center
Table 12.29 Grants Analysis: Distribution by Administering Institute Center
Table 12.30 Grants Analysis: Distribution by Support Period
Table 12.31 Popular Recipient Organization: Distribution by Number of Grants
Table 12.32 Grants Analysis: Distribution by Type of Recipient Organization
Table 12.33 Grants Analysis: Distribution by Purpose of Grant
Table 12.34 Grants Analysis: Distribution by Study Section
Table 12.35 Popular NIH Departments: Distribution by Number of Grants
Table 12.36 Grants Analysis: Distribution by Administering Institute Center and Support Period
Table 12.37 Grants Analysis: Distribution by Type of Type of Grant Application
Table 12.38 Grants Analysis: Distribution by Grant Activity Code
Table 12.39 Prominent Program Officers: Distribution by Number of Grants
Table 12.40 Grants Analysis: Distribution by Location of Recipient Organization
Table 12.41 Partnerships and Collaborations: Distribution by Year of Partnership
Table 12.42 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.43 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 12.44 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 12.45 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 12.46 Most Active Players: Distribution by Number of Partnerships
Table 12.47 Partnerships and Collaborations: Distribution by Region
Table 12.48 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 12.49 Patent Analysis: Distribution by Type of Patent
Table 12.50 Patent Analysis: Distribution by Patent Publication Year
Table 12.51 Patent Analysis: Distribution by Annual Number of Granted Patents
Table 12.52 Patent Analysis: Distribution by Geographical Location
Table 12.53 Patent Analysis: Distribution by Jurisdiction
Table 12.54 Patent Analysis: Distribution by Type of Applicant
Table 12.55 Patent Analysis: Distribution by Patent Age
Table 12.56 Leading Industry Players: Distribution by Number of Patents
Table 12.57 Leading Non-Industry Players: Distribution by Number of Patents
Table 12.58 Leading Individual Assignees: Distribution by Number of Patents
Table 12.59 Patent Valuation: Distribution by Relative Valuation
Table 12.60 Global Genotoxicity Testing / Mutagenicity Testing Market, 20232-2035 (USD Million)
Table 12.61 Genotoxicity Testing / Mutagenicity Testing Market, 2023-2035: Distribution by Type of Assay
Table 12.62 Genotoxicity Testing / Mutagenicity Testing Market for In vivo Assays, 2023-2035 (USD Million)
Table 12.63 Genotoxicity Testing / Mutagenicity Testing Market for In vitro Assays, 2023-2035 (USD Million)
Table 12.64 Genotoxicity Testing / Mutagenicity Testing Market for Non-GLP / Screening Assays, 2023-2035 (USD Million)
Table 12.65 Genotoxicity Testing / Mutagenicity Testing Market, 2023-2035: Distribution by Assay / Test Offered
Table 12.66 Genotoxicity Testing / Mutagenicity Testing Market for Comet Assays, 2023-2035 (USD Million)
Table 12.67 Genotoxicity Testing / Mutagenicity Testing Market for Micronucleus Assays, 2023-2035 (USD Million)
Table 12.68 Genotoxicity Testing / Mutagenicity Testing Market for Chromosomal Aberration Tests, 2023-2035 (USD Million)
Table 12.69 Genotoxicity Testing / Mutagenicity Testing Market for Genetic Mutation Tests, 2023-2035 (USD Million)
Table 12.70 Genotoxicity Testing / Mutagenicity Testing Market for Other Tests, 2023-2035 (USD Million)
Table 12.71 Genotoxicity Testing / Mutagenicity Testing Market, 2023-2035: Distribution by End User Industry
Table 12.72 Genotoxicity Testing / Mutagenicity Testing Market for Chemical Industry, 2023-2035 (USD Million)
Table 12.73 Genotoxicity Testing / Mutagenicity Testing Market for Healthcare Industry, 2023-2035 (USD Million)
Table 12.74 Genotoxicity Testing / Mutagenicity Testing Market for Agriculture Industry, 2023-2035 (USD Million)
Table 12.75 Genotoxicity Testing / Mutagenicity Testing Market for Cosmetic Industry, 2023-2035 (USD Million)
Table 12.76 Genotoxicity Testing / Mutagenicity Testing Market for Other Industries, 2023-2035 (USD Million)
Table 12.77 Genotoxicity Testing / Mutagenicity Testing Market, 2023 and 2035: Distribution by Geographical Region
Table 12.78 Genotoxicity Testing / Mutagenicity Testing Market in North America, 2023-2035 (USD Million)
Table 12.79 Genotoxicity Testing / Mutagenicity Testing Market in Europe, 2023-2035 (USD Million)
Table 12.80 Genotoxicity Testing / Mutagenicity Testing Market in Asia-Pacific, 2023-2035 (USD Million)
Table 12.81 Genotoxicity Testing / Mutagenicity Testing Market in Latin America, 2023-2035 (USD Million)
Table 12.82 Genotoxicity Testing / Mutagenicity Testing Market in Middle East and North Africa, 2023-2035 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. Admescope (acquired by Symeres)
  2. Aelan Cell Technologies
  3. Amelia Technologies
  4. Anax Laboratories
  5. Anthem Biosciences
  6. Aragen Life Sciences
  7. Aurigene Pharmaceutical Services
  8. Beijing Sun-Novo Pharmaceutical Research
  9. Binzhou Medical University
  10. BioDuro-Sundia
  11. Bioneeds
  12. BioReliance (acquired by Sigma-Aldrich)
  13. Bioscience Research Foundation (BRF)
  14. Biotrial
  15. Bolder BioPATH
  16. BRI Biopharmaceutical Research
  17. Brown University
  18. BSL BIOSERVICE
  19. Cadila Pharmaceuticals
  20. Charles River Laboratories
  21. Citoxlab (acquired by Charles River Laboratories)
  22. Creative Bioarray
  23. Creative Biolabs
  24. Crown Bioscience
  25. CSIR- Indian Institute of Toxicology Research
  26. Curza
  27. Cyprotex (acquired by Evotec)
  28. Dabur Research Foundation
  29. DigilenceBio
  30. Edara Research Foundation (ERF)
  31. EMTAC Laboratories (a subsidiary of Vimta Labs)
  32. (EBPI) Environmental Bio-Detection Products
  33. Eurofins Scientific
  34. ERBC (European Research Biology Center)
  35. Evotec
  36. Experimur
  37. Forschungsverbund Berlin
  38. Frontage Clinical Services (acquired by Frontage Laboratories)
  39. Frontage Laboratories
  40. GenEvolutioN (spin-off from Seqens)
  41. Gentronix
  42. Gerresheimer
  43. GLR Laboratories
  44. GV Research Platform
  45. Helix3
  46. University Hospital Center of Toulouse
  47. IIT Research Institute (IITRI)
  48. Inotiv
  49. InStem
  50. Integrated Laboratory Systems (acquired by Inotiv)
  51. International Institute of Biotechnology and Toxicology
  52. Intertek
  53. Intox (acquired by Aragen Life Sciences)
  54. ITR Laboratories
  55. Jai Research Foundation
  56. JDM Research
  57. Jubilant Chemsys
  58. Jubilant Life Sciences
  59. Kangpu Biopharmaceuticals
  60. Korea Research Institute of Bioscience & Biotechnology
  61. Korea University Research and Business Foundation
  62. Krish Biotech Research
  63. LabCorp
  64. LAUS
  65. LeadScope
  66. Leiden University
  67. Litron Laboratories
  68. LSIM Safety Institute
  69. Lupin
  70. Massachusetts Institute of Technology
  71. Max Delbrück Center for Molecular Medicine
  72. MB Biosciences
  73. MB Research Laboratories
  74. Medical and Biological Laboratories
  75. Medicilon
  76. Megsan Labs
  77. Symeres (formerly known as MercachemSyncom)
  78. Merck    
  79. MilliporeSigma
  80. MPI Research
  81. Nanjing Pharmaceutical Factory
  82. National Autonomous University of Mexico
  83. National Institute for Health and Medical Research (INSERM)
  84. National Institute of Occupational Health
  85. Natural Remedies
  86. Nelson Labs (a subsidiary of Sotera Health)
  87. Nucro-Technics
  88. Pacific BioLabs
  89. Palamur Biosciences
  90. Paul Sabatier University
  91. PhoenixBio
  92. Pre-Clinical Research Services (acquired by Inotiv)
  93. PrediTox
  94. Profacgen
  95. Qilu Pharmaceutical
  96. RCC Laboratories
  97. Reliance Life Sciences
  98. Ribosome Research Center
  99. Sa-Ford
  100. Sai Life Sciences
  101. SenzaGen
  102. Shriram Institute for Industrial Research
  103. SIRO Clinpharm
  104. Smithers Avanza
  105. South China University of Technology
  106. Ssp
  107. Stallergenes Greer
  108. Stanford University
  109. Sun Pharma Advanced Research Company
  110. Syngene
  111. Taipei Medical University
  112. Texas Pacific Group
  113. Torrent Pharmaceuticals
  114. Toxicology Research Laboratory (a part of University of Illinois Chicago)
  115. Toxi-Coop
  116. Toxikon (acquired by LabCorp)
  117. Toxys
  118. TÜV SÜD
  119. TwinStrand Biosciences
  120. Unilever Safety and Environmental Assurance
  121. University of Washington
  122. University of California
  123. UT Southwestern Medical Center
  124. Vanta Bioscience
  125. Veeda Clinical Research
  126. Vimta Labs
  127. Vipragen Biosciences
  128. Vivo Bio Tech
  129. Vivotecnia
  130. Xenometrix
  131. Zhuhai Rundu Pharmaceutical
  132. Zyirn Research Consultancy Services

Source 1: https://www.news-medical.net/life-sciences/What-is-Genotoxicity-Testing.aspx
Source 2: https://pubmed.ncbi.nlm.nih.gov/19157059/

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.